The latest price target for Immunome (NASDAQ:IMNM) was reported by Craig-Hallum on March 4, 2026. The analyst firm set a price target for $36.00 expecting IMNM to rise to within 12 months (a possible 58.73% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Craig-Hallum, and Immunome maintained their buy rating.

There is no last upgrade for Immunome

There is no last downgrade for Immunome.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on March 4, 2026 so you should expect the next rating to be made available sometime around March 4, 2027.

While ratings are subjective and will change, the latest Immunome (IMNM) rating was a maintained with a price target of $33.00 to $36.00. The current price Immunome (IMNM) is trading at is $22.68, which is out of the analyst’s predicted range.